Everything below concerns mass spectrometry. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
Stability of AOD-9604 depends on storage conditions. Lyophilized powder is generally more stable than reconstituted solution. Recommended storage is typically at -20°C or lower, protected from light and moisture. Repeated freeze-thaw cycles can cause aggregation or degradation. In solution, the peptide may be susceptible to hydrolysis or oxidation, so aliquoting and cold storage are common practices. Researchers often add stabilizers such as mannitol or trehalose during lyophilization to improve shelf life.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
=== As food === Journalist Alistair Cooke claimed that rattlesnake tastes "just like chicken, only tougher". Others have compared the flavor to a wide range of other meats, including veal, frog, tortoise, quail, fish, rabbit, and even canned tuna. Methods of preparation include barbecueing and frying; author Maud Newton, following a recipe by Harry Crews, described the taste, "at least when breaded and fried, like a sinewy, half-starved tilapia."
=== Gaining strength === Liu Wenhui took advantage of the Sichuanese conflicts to gain power. In 1924, he gave financial support to Liu Xiang and Yang Sen in their campaign to oust Xiong Kewu's forces; in return, the two warlords allowed him to take control of a part of the defeated Xiong's army and territories. In October 1925, after Yang Sen's defeat in a military conflict, Liu again incorporated part of the losing party's armies and territories, expanding his influence to Meishan and Leshan. Chief Executive Duan Qirui also appointed him as the Assistant Military Affairs Commissioner for Sichuan. When his former commander Chen Hongfan was attacked by Yang Sen's forces, Liu offered him no help and even refused an appeal by Leng Yingdong to let Chen serve in his government. Instead, Liu absorbed Chen's remaining forces; Chen subsequently returned to Dayi County in disgrace and reportedly went mad. During the May Thirtieth Movement, students in Yibin staged a boycott of British goods and clashed with British merchants. Liu Wenhui's military police arrested the student leaders, sparking outrage, but Liu met with the students and made an anti-imperialist speech mentioning his connections to the patriot Jiang Baili. To prove that his prisoners were not being tortured, Liu let demonstrators observe that they were playing basketball in the prison courtyard. In the wake of the Northern Expedition and the First United Front, Liu began flirting with progressive ideas. Around 1926, Liu appointed Communist Party member Liu Yuan'an as one of his senior advisors.
He also founded the Collective Investigation Record for the British Medical Association; this organization collected data from physicians practicing outside the hospital setting and was the precursor of modern collaborative clinical trials."
Sources: en.wikipedia.org
Dried timber is lighter, and the transportation and handling costs are reduced. Dried timber is stronger than green timber in most strength properties. Timbers for impregnation with preservatives have to be properly dried if proper penetration is to be accomplished, particularly in the case of oil-type preservatives. In the field of chemical modification of wood and wood products, the material should be dried to a certain moisture content for the appropriate reactions to occur. Dry wood generally works, machines, finishes and glues better than green timber (although there are exceptions; for instance, green wood is often easier to turn than dry wood). Paints and finishes last longer on dry timber. The electrical and thermal insulation properties of wood are improved by drying. Prompt drying of wood immediately after felling therefore significantly upgrades and adds value to raw timber. Drying enables substantial long-term economy by rationalizing the use of timber resources. The drying of wood is thus an area for research and development, which concern many researchers and timber companies around the world.
== Biological function == In 1962, J.C. Watkins reported synthesizing NMDA, an isomer of the previously known N-Methyl-DL-aspartic-acid. NMDA is a water-soluble D-alpha-amino acid — an aspartic acid derivative with an N-methyl substituent and D-configuration — found across Chordates from lancelets to mammals. At homeostatic levels NMDA plays an essential role as a neurotransmitter and neuroendocrine regulator. At increased but sub–toxic levels NMDA becomes neuroprotective. In excessive amounts NMDA is an excitotoxin. Behavioral neuroscience research utilizes NMDA excitotoxicity to induce lesions in specific regions of an animal subject's brain or spinal cord to study behavioral changes. The mechanism of action for the NMDA receptor is a specific agonist binding to its NR2 subunits, and then a non-specific cation channel is opened, which can allow the passage of Ca2+ and Na+ into the cell and K+ out of the cell. Therefore, NMDA receptors will only open if glutamate is in the synapse and concurrently the postsynaptic membrane is already depolarized - acting as coincidence detectors at the neuronal level. The excitatory postsynaptic potential (EPSP) produced by activation of an NMDA receptor also increases the concentration of Ca2+ in the cell. The Ca2+ can in turn function as a second messenger in various signaling pathways. This process is modulated by a number of endogenous and exogenous compounds and plays a key role in a wide range of physiological (such as memory) and pathological processes (such as excitotoxicity).
=== Lipton Yellow Label === Lipton Yellow Label tea has been sold since 1890, when Sir Thomas Lipton introduced the first version of the yellow pack with a red Lipton shield that is still in use today. It is sold in 150 countries worldwide. Lipton Yellow Label is a blend of several types of tea, sold both in tea bags and as loose tea, rolled into small leaves like gunpowder green tea.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.